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Introduction {#s1}
============

Type 2 diabetes (T2D) has become a common and serious global health problem due to genetic factors and changes in diet and life style. Insulin-stimulated glucose uptake is severely impaired in T2D, which may be due to insulin resistance in skeletal muscle and adipocytes, a key feature of T2D. Along with this insulin resistance, a relevant role in maintaining hyperglycemia is played by an impaired basal glucose uptake, which was reduced by\>30% in relatively non-insulin sensitive organs such as kidney and skin [@pone.0116203-Schwartz1]. Hence the identification of novel pathways that can increase glucose uptake independent of insulin signaling pathways is of great therapeutic interest.

Extracellular nucleotides act as signaling molecules in many physiological processes by activating cell surface P2 receptors [@pone.0116203-Burnstock1]. The P2Y family of G protein-coupled receptors, which are activated by various endogenous mono- and dinucleotides, has a role in processes related to diabetes. The P2Y~6~ receptor (P2Y~6~R) is a G~q~-coupled receptor that is activated by uridine 5′-diphosphate (UDP **1**, [Fig. 1](#pone-0116203-g001){ref-type="fig"}) and acts through phospholipase Cβ to induce inositol lipid signaling. It is highly expressed in dendritic cells, cardiomyoctes, liver, placenta and other sites [@pone.0116203-Communi1]. Also, P2Y~6~R mRNA is expressed in high levels in smooth muscle cells, kidney and spleen, and in moderate levels in lung, intestine, adipose tissue, bone and heart [@pone.0116203-Moore1]. P2Y~6~R activation is associated with antiapoptotic effects dependent on protein kinase C and extracellular signal-regulated kinases in skeletal muscle and pancreatic β-islet cells [@pone.0116203-Kim1]--[@pone.0116203-Balasubramanian1]. The cytoprotection induced by UDP acting at the P2Y~6~R is not observed with other G~q~-coupled P2YRs, e.g. the action of UTP at the P2Y~4~R or 2-methylthio-ADP at the P2Y~1~R. Furthermore, UDP and other P2Y~6~R agonists increase glucose-dependent release of insulin from mouse pancreatic β-islet cells (MIN6) and primary mouse islets [@pone.0116203-Balasubramanian1], [@pone.0116203-Parandeh1]. Endogenous UDP has been shown to activate P2Y~6~R to contribute to insulin secretion in vivo in the mouse [@pone.0116203-Sassmann1]. A role for the ADP-responsive P2Y~13~R in pancreatic β-islet cells has also been demonstrated [@pone.0116203-Amisten1].

![Structures of P2Y~6~R ligands: nucleotide agonists.](pone.0116203.g001){#pone-0116203-g001}

The structure activity relationships (SARs) at the P2Y~6~R have been explored through the synthesis of nucleotide agonists and non-nucleotide antagonists [@pone.0116203-Mamedova2]--[@pone.0116203-GinsburgShmuel1]. Various pyrimidine nucleotides have been reported as selective agonists, e.g. nucleoside 5′-diphosphates **2**--**4** and dinucleoside (5',5')-triphosphates **5** and **6** [@pone.0116203-Maruoka1]--[@pone.0116203-GinsburgShmuel1], while the only selective antagonists yet reported are irreversibly acting isothiocyanate derivatives [@pone.0116203-Mamedova2]. In our recent work, we have reported that P2Y~6~R-selective agonist P^1^-(5′-uridine)-P^3^-(5′-*N^4^*-methoxycytidine)-triphosphate (MRS2957, **6**) activates 5′-AMP-activated protein kinase (AMPK) in MIN6 mouse β-islet cells through a calmodulin-dependent protein kinase kinase (CaMKK)β signaling pathway [@pone.0116203-Balasubramanian1]. AMPK has been widely reported as a target for treatment of T2D, and it acts indirectly to increase insulin-independent glucose uptake [@pone.0116203-Merlin1]. Activation of AMPK by 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) increases glucose uptake in skeletal muscle in the diabetic mouse and human, independent of insulin signaling [@pone.0116203-Song1], [@pone.0116203-Koistinen1]. Apart from regulation of cellular energy pathways, AMPK also increases translocation of the facilitated glucose transporter-4 (GLUT4) and thus promotes glucose uptake in skeletal muscle [@pone.0116203-KurthKraczek1].

Other G~q~-coupled receptors are known to promote glucose uptake in insulin target tissues. For example, glucose uptake was stimulated by activation of the endothelin-1 receptor in 3T3-L1 adipocytes and the M~3~-muscarinic acetylcholine receptor in L6 skeletal muscle cells, an effect dependent on both CaMKK and AMPK [@pone.0116203-Merlin1], [@pone.0116203-Rachdaoui1]. The effects of purinergic agonists on glucose uptake have been explored, but the association with specific receptor subtypes, either P2YRs or P2X ion channels has not yet been established [@pone.0116203-Karczewska1]. In this context, we characterized the effects of P2Y~6~R activation on glucose uptake in skeletal muscle and adipocytes and the involvement of AMPK and other associated signaling pathways.

Results {#s2}
=======

We selected two cell lines for examination of the effects of P2Y~6~R agonists on glucose uptake in target tissues: C2C12 mouse skeletal myoblasts and 3T3-L1 mouse fibroblasts that differentiate into adipocytes. We already demonstrated a pharmacological effect of the P2Y~6~R in C2C12 cells, i.e. protection against TNFα-induced apoptosis [@pone.0116203-Mamedova1].

P2Y~6~R agonist stimulates glucose uptake {#s2a}
-----------------------------------------

Glucose is the key energy source in skeletal muscle, and glucose transport is the rate-determining step in glucose-dependent intracellular energy production. We evaluated the efficacy of P2Y~6~R agonist MRS2957 to stimulate glucose uptake in differentiated C2C12 cells ([Fig. 2A](#pone-0116203-g002){ref-type="fig"}) and in 3T3-L1 adipocytes ([Fig. 2B](#pone-0116203-g002){ref-type="fig"}). Treatment with MRS2957 (100 nM) significantly increased glucose uptake in both C2C12 cells and 3T3-L1 adipocytes when compared to control cells. In 3T3-L1 adipocytes, a concentration-dependent increase was observed upon treatment with 100 nM MRS2957. Also, glucose uptake induced by MRS2957 (100 nM) was not significantly different from that induced by insulin (200 nM). The effect of the P2Y~6~R agonist was blocked by pre-treatment with P2Y~6~R antagonist *N*,*N*″-1,4-butanediyl-*bis*\[*N′*-(3-isothiocyanatophenyl)thiourea\] (MRS2578, 1 µM) in both cell lines. This shows that the increase in glucose uptake by MRS2957 occurs through activation of the P2Y~6~R. The concentration of MRS2957 at 100 nM was chosen based on our studies with various concentrations of MRS2957 ([S1 Fig](#pone.0116203.s001){ref-type="supplementary-material"}.). Glucose uptake in cells co-treated with insulin and MRS2957 did not show any significant difference when compared to cells treated with insulin alone ([S2 Fig](#pone.0116203.s002){ref-type="supplementary-material"}.).

![(A and B). Effects of P2Y~6~R agonist MRS2957 on glucose uptake in C2C12 cells (A) and 3T3-L1 cells (B).\
MRS2957 was applied in the presence or absence of P2Y~6~R antagonist MRS2578 (1 µM). \**P*\<0.05, when compared to controls (n = 3).](pone.0116203.g002){#pone-0116203-g002}

Role of AMPK in P2Y~6~R-mediated glucose uptake {#s2b}
-----------------------------------------------

To explore the mechanism involved in the P2Y~6~R-mediated glucose uptake, we evaluated AMPK and mitogen-activated protein kinases (MAPK) in myotubes and adipocytes. P2Y~6~R ligands have already been reported to activate MAPK [@pone.0116203-Mamedova1] and AMPK [@pone.0116203-Balasubramanian1], which are known to be involved in glucose uptake [@pone.0116203-Koistinen1]. We used inhibitors of MAPK (1,4-diamino-2,3-dicyano-1,4-bis-(2-aminophenylthio)butadiene, U0126, 10 µM) and AMPK (6-\[4-(2-piperidin-1-yl-ethoxy)-phenyl)\]-3-pyridin-4-yl-pyrrazolo\[1,5-a\]-pyrimidine, Compound C, 10 µM) to study their effect on P2Y~6~R-mediated glucose uptake. Preincubation with MAPK inhibitor U0126 did not affect the P2Y~6~R agonist-induced glucose uptake in either C2C12 myotubes ([Fig. 3A](#pone-0116203-g003){ref-type="fig"}) or 3T3-L1 adipocytes (using MRS2957, [Fig. 3B](#pone-0116203-g003){ref-type="fig"}). In contrast, preincubation with Compound C followed by treatment with MRS2957 significantly reduced glucose uptake when compared to cells treated with MRS2957 alone. The effects of U0126 or Compound C alone did not differ from control. This shows that AMPK is involved in glucose uptake induced by the P2Y~6~R agonist MRS2957. To further confirm this result we also used small interfering RNA (siRNA) for AMPK to silence the expression of AMPK in C2C12 myotubes and 3T3-L1 adipocytes ([Fig. 4A and 4B](#pone-0116203-g004){ref-type="fig"}). In the absence of AMPK, treatment with MRS2957 failed to increase glucose uptake in both of the cell lines. Thus, we were able to confirm the role of AMPK in P2Y~6~R-mediated glucose uptake. Also, there were no changes in MRS2957-induced glucose uptake in both the cell lines when transfected with a scrambled siRNA control ([S3 Fig](#pone.0116203.s003){ref-type="supplementary-material"}.).

![(A and B). Effects of inhibitors of intracellular signaling pathways on P2Y~6~R-mediated glucose uptake.\
C2C12 cells (A) or 3T3-L1 cells (B) were preincubated with inhibitors of MAPK (U0126, 10 µM) and AMPK (Compound C, 10 µM) followed by treatment with P2Y~6~R agonist MRS2957. \* *P*\<0.05, when compared to controls, ^\#^ *P*\<0.05, when compared to MRS2957, 100 nM (n = 3).](pone.0116203.g003){#pone-0116203-g003}

![Glucose uptake in C2C12 myotubes (A) and 3T3-L1 adipocytes (B) transfected with AMPK siRNA.\
\**P*\<0.05, when compared to controls, NS, non-significant when compared to controls (n = 3).](pone.0116203.g004){#pone-0116203-g004}

We have previously demonstrated the efficacy of MRS2957 in the activation of AMPK in MIN6 cells [@pone.0116203-Balasubramanian1]. Now, we examined the ability of MRS2957 to activate AMPK in both C2C12 myotubes ([Fig. 5](#pone-0116203-g005){ref-type="fig"}) and 3T3-L1 adipocytes ([Fig. 6](#pone-0116203-g006){ref-type="fig"}). Differentiated cells were treated with MRS2957 (100 nM) with or without MRS2578 (1 µM) for 1 h, and the cells were lysed and proteins were immunoblotted and probed with phospho-AMPK antibody. Treatment with MRS2957 resulted in significant phosphorylation of AMPK in both of the cells lines. This shows that AMPK signaling is involved in P2Y~6~R-mediated glucose uptake in skeletal muscle and differentiated adipocyte cell lines.

![Phosphorylation of AMPK in C2C12 myotubes (A and B) after treatment with MRS2957.\
This is a representative blot from three individual experiments. The density of the bands were quantified and compared to the controls (B and D). \**P*\<0.05, when compared to controls, NS, non-significant when compared to controls (n = 3). **Lane 1**, Control, **2**, MRS2957 (100 nM), **3**, MRS2578(1 µM), **4**, MRS2578+ MRS2957, **5**, AICAR (200 µM), **6**, Suramin (20 µM)+MRS2957.](pone.0116203.g005){#pone-0116203-g005}

![Phosphorylation of AMPK in 3T3-L1 adipocytes (A and B) after treatment with MRS2957.\
This is a representative blot from three individual experiments. The density of the bands were quantified and compared to the controls (B and D). \**P*\<0.05, when compared to controls, NS, non-significant when compared to controls (n = 3). **Lane 1**, Control, **2**, MRS2957 (100 nM), **3**, MRS2578(1 µM), **4**, MRS2578+ MRS2957, **5**, AICAR (200 µM), **6**, Suramin (20 µM)+MRS2957.](pone.0116203.g006){#pone-0116203-g006}

GLUT4 Translocation {#s2c}
-------------------

In the presence of appropriate extracellular stimuli, GLUT1 and GLUT4 are recruited to the plasma membrane and/or activated to facilitate glucose transport [@pone.0116203-Olson1]. To evaluate if P2Y~6~R recruits glucose transporters in C2C12 cells and 3T3-L1 adipocytes, we examined by Western blotting the changes in the levels of glucose transporter GLUT4 in the plasma membrane upon activation of P2Y~6~R. As shown in [Fig. 7](#pone-0116203-g007){ref-type="fig"} (A&B), the plasma membrane localization of GLUT4 is high in adipocytes treated with MRS2957 when compared to that of the control adipocytes.

![Translocation of glucose transporters GLUT4 in the plasma membrane upon activation of P2Y~6~R.\
(A) Immunoblotting is used to determine the changes in the membrane levels of the GLUT4 transporter. This is a representative blot from three individual experiments. Key to lanes: **1**--**3**, C2C12 myotubes; **4**--**6**, 3T3-L1 adipocytes. **1** and **4**, controls; **2** and **5**, MRS2957, 100 nM; **3** and **6**, 200 nM insulin. (B) GLUT4/β-actin ratio based on the quantitation of the bands.](pone.0116203.g007){#pone-0116203-g007}

Glucose uptake in primary adipocytes by P2Y~6~R activation {#s2d}
----------------------------------------------------------

To evaluate the efficacy of a P2Y~6~R agonist in increasing glucose uptake in primary mouse adipocytes we isolated adipocytes from both wild-type (WT) and P2Y~6~R-knockout mice. The stromal vascular fraction (SVF) of adipose tissue, a rich source of preadipocytes, was isolated from mouse using the procedure described in the [Materials and Methods](#s4){ref-type="sec"} section. The preadipocytes were differentiated into adipocytes and used to evaluate the efficiency of P2Y~6~R agonists UDP and MRS2957 to stimulate glucose uptake. In adipocytes from WT mice ([Fig. 8A](#pone-0116203-g008){ref-type="fig"}), MRS2957 treatment resulted in a significant increase in glucose uptake when compared to basal levels. Moreover, preincubation with MRS2578 abated the increase in glucose uptake by MRS2957. In the case of adipocytes isolated from P2Y~6~-knockout (KO) mice ([Fig. 8B](#pone-0116203-g008){ref-type="fig"}), there was no significant difference in glucose uptake between MRS2957-treated and control adipocytes. Note, however, that insulin-stimulated glucose uptake was intact in the adipocytes from KO mice. This demonstrates that P2Y~6~R activation may lead to increased glucose uptake in primary adipocytes. Also, we observed a decrease in the basal glucose uptake in P2Y~6~R KO primary adipocytes when compared to that of the WT, although the significance of this difference is not clear.

![Glucose uptake assay in primary adipocytes isolated from WT (A) and P2Y~6~R-KO mice (B).\
\**P*\<0.05, when compared to controls, NS, non-significant when compared to controls (n = 3).](pone.0116203.g008){#pone-0116203-g008}

Effects of AMPK on HDAC5 {#s2e}
------------------------

AMPK is known to stimulate GLUT4 transcription by phosphorylating the enzyme histone deacetylase 5 (HDAC5), thereby preventing its association with the GLUT4 promoter and the resulting repression of transcription [@pone.0116203-McGee1]. Our results show that the P2Y~6~R activates AMPK, which results in increased glucose uptake. To determine if the mechanism involves HDAC5 regulation of the GLUT4 pathway, we performed a chromatin immunoprecipitation (ChIP) assay using C2C12 myotubes treated with MRS2957, MRS2578+MRS2957 or AICAR, and the chromatin was immunoprecipitated using an anti-HDAC5 antibody. The DNA was amplified using primers for HDAC5 associated with the GLUT4 promoter surrounding the region for the myocyte enhancer factor (MEF) 2. The gene amplification by qPCR indicated that the association of HDAC5 with the GLUT4 promoter was significantly reduced in MRS2957-treated C2C12 cells, and similar results were observed in C2C12 myotubes treated with AMPK activator AICAR ([Fig. 9](#pone-0116203-g009){ref-type="fig"}). Also, preincubation with antagonist MRS2578 followed by treatment with MRS2957 reversed the decrease in GLUT4 promoter association to HDAC5. These results are consistent with our hypothesis that activation of P2Y~6~R activates AMPK, which inhibits HDAC5 and consequently results in increased GLUT4 expression in C2C12 myotubes.

![HDAC5 associated GLUT4 promoter DNA in the MEF2 binding region following treatment with MRS2957 (100 nM) or AICAR (200 µM) or MRS2578 (1 µM)+MRS2957 in C2C12 myotubes using ChIP assay.\
\**P*\<0.05, when compared to controls, ^\#^ *P*\<0.05, when compared to MRS2578+ MRS2957 (n = 3).](pone.0116203.g009){#pone-0116203-g009}

Discussion {#s3}
==========

We demonstrate here that glucose uptake in skeletal myocytes and adipocytes in culture is increased in the presence of a P2Y~6~R agonist MRS2957. This agonist is more potent than UDP at the human P2Y~6~R (EC~50~ 12 nM, compared to 300 nM for UDP) [@pone.0116203-Maruoka1]. Glucose uptake in primary mouse adipocytes was also stimulated upon P2Y~6~R activation by UDP and MRS2957. Thus, a P2Y~6~R agonist would be expected to produce beneficial effects for diabetes both with respect to insulin release from the pancreas and glucose homeostasis in certain insulin target tissues. However, it is not clear if this approach is clinically relevant, because proinflammatory effects of P2Y~6~R activation, such as in the allergic airway and the vasculature, have also been reported [@pone.0116203-Vieira1]--[@pone.0116203-Guns1].

A role for the regulation of GLUT4 expression by HDAC in both skeletal muscle cells and mature adipocytes has been reported previously [@pone.0116203-McGee1], [@pone.0116203-Weems1]--[@pone.0116203-Mukwevho1]. A conserved binding site for the MEF2 transcription factor is essential for the normal expression of skeletal muscle GLUT4. A direct correlation between reduced MEF2 expression and reduced GLUT4 expression has been reported. Studies have also shown a link between class II histone deacetylases (HDACs) in the regulation of GLUT4 expression in various cell types. HDAC5 acts as a repressor of GLUT4 expression by its association with MEF2. It has also been reported that AMPK phosphorylates HDAC5 to convert it to its inactive form, and consequently to increase GLUT4 expression [@pone.0116203-McGee1]. Our study using a ChIP assay showed that treatment with MRS2957 decreased HDAC5 occupancy of the GLUT4 promoter region in C2C12 myotubes. Based on this result, we hypothesized that treatment with MRS2957 activates AMPK, which inactivates HDAC5 by phosphorylation and thus results in increased GLUT4 expression leading to increased glucose uptake. HDAC inhibition has been suggested for the treatment of diabetes [@pone.0116203-Christensen1], further emphasizing the possible disease relevance of the inhibitory influence of P2Y~6~R activation.

The action of UDP at the P2Y~6~R was not previously implicated in glucose uptake in insulin target tissues, but nucleotide effects through other P2 receptors were reported. Previous reports initially indicated that activation of the G~q~-coupled P2Y~2~R might be beneficial in diabetes by stimulating glucose uptake [@pone.0116203-Inazuka1], [@pone.0116203-Solini1]. Extracellular ATP enhanced glucose transport in human fibroblasts via GLUT1, but the P2Y-dependent activation of GLUT1 was found to be deficient in fibroblasts from T2D individuals [@pone.0116203-Solini1]. Also, the vasodilatory response to P2Y~2~R activation by ATP or UTP is severely attenuated in diabetic patients [@pone.0116203-Thaning1]. Thus, a P2Y~2~R agonist is not likely to be useful for treatment of diabetes because of changes in the receptor responsiveness in the pathological state. Also, side effects of these nucleotides might interfere with their beneficial effects. For example, ATP enhanced uptake by Na^+^-glucose cotransporters in rabbit renal proximal tubule cells in a manner dependent on P2YRs, G~i~ protein, 3′-5′-cyclic adenosine monophosphate and p38 MAPK [@pone.0116203-Lee1]. Thus, this P2Y~2~R-dependent activation of Na^+^-glucose cotransporters would be detrimental in diabetes. Recently, it was suggested that activation of other classes of G~q~-coupled receptors present in the β-islet cells and target tissues might be similarly advantageous [@pone.0116203-Jain1], [@pone.0116203-Li1]. The stimulation of a G~q~-coupled M~3~ muscarinic acetylcholine receptor was shown to be beneficial with respect to pancreatic β-cells and liver in diabetic animal models. It is not known if the G~q~-coupled P2Y~6~R responses are maintained in diabetic patients or whether the proinflammatory responses, vasoconstriction and other detrimental effect already ascribed to P2Y~6~R activation [@pone.0116203-Vieira1]--[@pone.0116203-Bar1] would preclude use of such agonists in diabetes treatment.

Nevertheless, we have found that P2Y~6~R activation by both UDP and a synthetic potent and selective agonist enhanced glucose transport in two different cell lines and primary cells from mouse. This suggests a potential benefit with respect to defective glucose metabolism, which is known to be associated with diabetes in peripheral tissues such as skeletal muscles and adipocytes. The effect of P2Y~6~R agonists on glucose uptake in other target tissues, such as the brain and liver, remain to be determined. This phenomenon needs to be explored in vivo and particularly in diabetic models in order to establish its relevance to diabetes treatment.

Materials and Methods {#s4}
=====================

Materials {#s4a}
---------

P2Y~6~R antagonist MRS2578 and P2Y~6~R agonist MRS2957 were purchased from Tocris Bioscience (Ellisville, MO) or prepared as described [@pone.0116203-Maruoka1]. Cytochalasin-B, Compound C (dorsomorphin) and U0126 monoethanolate were from Sigma-Aldrich (St. Louis, MO). Antibodies to phospho-AMPK, AMPKα1/2, and anti-mouse and anti-rabbit horseradish peroxidase-conjugated antibodies were purchased from Cell Signaling Technologies (Danvers, MA). P2Y~6~R specific antibody was from Alomone Labs Ltd. (Jerusalem, Israel). Goat anti-mouse IRDye 680LT and Goat anti-rabbit IRDye 800 CW were purchased from Li-Cor BioSciences (Lincoln, NE). All other reagents not mentioned were of the highest grade commercially available.

Cell culture {#s4b}
------------

C2C12 skeletal muscle cells (American Type Culture Collection, Manassas, VA) were grown at 37°C in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum until they reached 60--70% confluence and after which they were differentiated to myotubes using 2% horse serum and used for the experiments. 3T3-L1 mouse fibroblasts (American Type Culture Collection, Manassas, VA) were grown in DMEM containing 10% fetal bovine serum until they reached 70% confluence. Later, 3T3-L1 cells were differentiated into adipocytes using 0.5 mM 3-isobutyl-1-methylxanthine, 1 µM dexamethasone, 5 µg/ml insulin and 1 µg/ml thiazolidinedione for two days followed by incubation for 3 days with DMEM containing insulin (5 µg/ml).

\[^3^H\]2-Deoxy-D-glucose uptake assay {#s4c}
--------------------------------------

Uptake of \[^3^H\]2-deoxyglucose (PerkinElmer, Boston, MA) was measured in 3T3-L1 adipocytes and C2C12 myocytes differentiated in 24-well plates. After culture, cells were washed twice with serum-free DMEM and incubated in the serum-free DMEM for 2 h at 37°C. Cells were then washed twice in PBS and then incubated in Krebs ringer bicarbonate buffer containing 0.3% BSA in the presence or absence insulin or agonists and/or antagonists for 30 min at 37°C. Antagonists and inhibitors were added 30 min prior to the addition of P2Y~6~R agonist. After agonist treatment, uptake of 10 µM \[^3^H\]2-deoxyglucose was measured over 5 min. Reactions were terminated by rapidly washing the cells twice with ice-cold Krebs ringer bicarbonate buffer. Cell were then extracted by using 0.2% SDS, and the aliquots from the cell extracts were counted by liquid scintillation and used to determine protein concentration. Nonspecific uptake was measured in the presence of 10 µM of cytochalasin-B, and the values were subtracted from those of the specific binding.

Gene silencing by siRNA transfection {#s4d}
------------------------------------

AMPK siRNA (Santa Cruz Biotechnology, Dallas, TX) were used to silence the expression of AMPK gene in both C2C12 and 3T3-L1 cells by employing reverse transfection method. The complex of siRNA and transfection reagent was mixed with either fully confluent C2C12 cells or differentiated 3T3-L1 adipocytes and then transfected cells were allowed to grow for 2--3 days. The transfection was confirmed by Western blot against AMPK antibody. The transfected cells were used for glucose uptake assay. A control siRNA transfected cells were used as a control for the experiment.

Isolation of adipocytes from mouse {#s4e}
----------------------------------

Animal experiments were approved by NIDDK, National Institutes of Health (Animal Study Protocol \#K083-LBC-05). P2Y~6~R-knockout mice were generated by Bar et al. [@pone.0116203-Bar1], and we used these mice in our studies. Adipocytes were isolated from mouse as described [@pone.0116203-Ruan1]. In short, epididymal fat pads were removed, minced and digested using collagenase for 60--90 min at 37°C in Krebs-Ringer-bicarbonate-HEPES buffer. The stromal vascular fraction was separated from the adipocytes and cultured using DMEM and differentiated as described elsewhere [@pone.0116203-Aune1]. The differentiated adipocytes were used for the determination of glucose uptake.

Subcellular fractionation {#s4f}
-------------------------

Membrane fractions were prepared as described with some modifications [@pone.0116203-Shibata1]. Differentiated cells were stimulated with or without P2Y~6~R agonists for 60 min, and then the cells were washed with ice-cold PBS and homogenized in a buffer containing 10 mM Tris/HCl, 1 mM EDTA, 250 mM sucrose (pH 7.4) and protease inhibitors. The homogenate was centrifuged at 3000×g for 2 min. The supernatant was centrifuged at 20,000×g for 20 min and the pellet was suspended in 0.5 ml of the above buffer and layered on top of a liner (15%--35%) sucrose gradient and centrifuged for 60 min at 160,000×g. After the centrifugation, the plasma membrane fraction (1--3.5 cm from the bottom of the tube) was collected and the plasma membrane was pelleted by centrifugation for 60 min at 150,000×g. The pelleted plasma membrane fraction was used for GLUT4 assay by Western blot.

Western blot analysis {#s4g}
---------------------

Cell lysates (30 µg protein/well) were analyzed under reducing conditions by SDS-PAGE performed according to Laemmli [@pone.0116203-Laemmli1]. Proteins were separated on 12% BisTris gel (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes by electroblotting. Membranes were blocked according to the manufacturer's instructions and probed with specific antibodies overnight at 4°C. Subsequently, blots were probed with IRdye-conjugated secondary antibody for 1 h and then analyzed using an Odyssey infrared imaging system (Li-COR Biosciences, Lincoln, NE). Unless otherwise mentioned in the figure legends, the blots were scanned and images were captured using the Odyssey imaging system.

Chromatin immunoprecipitation assay {#s4h}
-----------------------------------

A ChIP assay was performed on using a kit (Cell Signaling Technology, Danvers,MA) according to the manufacturer's instructions. Differentiated C2C12 myotubes were treated with P2Y~6~R agonists and/or antagonist, and DNA-protein complexes were cross-linked using 1% formaldehyde for 15 min followed by quenching with 125 mmol/l glycine. Crosslinked chromatins were isolated from the cell lysate using nuclease digestion. HDAC5 was immunoprecipitated using an HDAC5 antibody (Active Motif, Carlsbad, CA) or unrelated antibody (mouse IgG) for controls. DNA was extracted and quantitative PCR was performed with primers designed to amplify GLUT4 promoter containing the MEF2 binding site using the following primers [@pone.0116203-Gong1]: 5′- CAG GCA TGG TCT CCA CAT ACA C-3′ (forward), 5′-GGT AAC TCC AGC AGG ATG ACA-3′ (reverse).

Statistical analysis {#s4i}
--------------------

Results are presented as mean ± SE (n = 3). Assays involving treatment with a single drug were analyzed by 1-way ANOVA with Tukey's multiple comparison test, and assays using more than one drug were analyzed using two-way ANOVA with Bonferroni post test. Differences between groups were rated significant at a probability error (*P*) \<0.05. For the Western blots, the intensity of the bands of the treated samples were calculated based on the intensity of the control sample and then the ratio was calculated to that of the internal controls. The graphical data were analyzed using the nonlinear curve-fitting program Prism 5.0 (GraphPad, San Diego, CA).
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**Glucose uptake efficacy of P2Y~6~R agonist MRS2957 at different doses in C2C12 myotubes and 3T3-L1 adipocytes.** C2C12 myotubes and 3T3-L1 adipocytes were treated with increasing dosage of MRS2957 and the glucose uptake was evaluated as described in the [Materials and Methods](#s4){ref-type="sec"} section. \**P*\<0.05, when compared to basal.

(PDF)

###### 

Click here for additional data file.

###### 

**Glucose uptake efficacy of MRS2957+Insulin in C2C12 myotubes and 3T3-L1 adipocytes.** C2C12 myotubes and 3T3-L1 adipocytes were co-treated with MRS2957 (100 nM) and insulin at either 200 nM or 500 nM concentration. \**P*\<0.05, when compared to basal; ^@^, not significant when compared to Insulin, 200 nM; ^\#^, not significant when compared to insulin, 500 nM; ^&^, *P*\<0.05, when compared to MRS2957 (100 nM).

(PDF)

###### 

Click here for additional data file.

###### 

**Glucose uptake with scrambled control siRNA in C2C12 myotubes and 3T3L1 adipocytes.** C2C12 myotubes and 3T3L1 adipocytes were transfected with scrambled control siRNA and was used for the glucose uptake assay after treatment with P2Y~6~R agonist MRS2957 (100 nM) or with MRS2578 (1 µM)+MRS2957 (100 nM). \**P*\<0.05, when compared to controls (n = 3).

(PDF)

###### 

Click here for additional data file.
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